previous compound ID: 1286 next compound
InChIKey: LNPDTQAFDNKSHK-UHFFFAOYSA-N
SMILES: CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N

biological descriptors:

CFTR relevance: unspecified

Category:
Influence on CFTR function unknown
Order of interaction unknown
subcellular compartment unknown

reference list:

ReferenceID: 53
"J Goepp" "E Matthes" "GW Carlile" "D Rotin" "B Kus" "SD Macknight" "DY Thomas" "J Liao" "JW Hanrahan" "R Robert"

chemical graph of compound 1286





CID is 119607
synonyms found at PubChem are:
Valdecoxib, 181695-72-7, Bextra, 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide, SC-65872, Valdyn, 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide, Kudeq, Valdecoxib [USAN], SC 65872, Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-, 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide, Valecoxib, YM-974, HSDB 7302, UNII-2919279Q3W, Valdecoxib (USAN/INN), CHEMBL865, p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide, CHEBI:63634, LNPDTQAFDNKSHK-UHFFFAOYSA-N, 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide, 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide, COX, ND-0214, NCGC00095129-01, 2919279Q3W, DSSTox_CID_24226, DSSTox_RID_80128, DSSTox_GSID_44226, 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide, C16H14N2O3S, 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide, Bextra(Valdecoxib), SMR000466327, CAS-181695-72-7, 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide, valdecoxibum, Vatdecoxib, Valdecoxib [USAN:INN:BAN], Valdecoxib/, Spectrum_001747, 2aw1, Spectrum2_000508, Spectrum3_001001, Spectrum4_001129, Spectrum5_001476, Pfizer brand of valdecoxib, D0L6DA, SCHEMBL3356, BSPBio_002721, KBioGR_001617, KBioSS_002227, MLS000759433, MLS001165699, MLS001195631, MLS001424105, SPECTRUM1504302, SPBio_000435, AC1L3P42, cid_119607, GTPL2894, ZINC6694, DTXSID6044226, Valdecoxib, >=98% (HPLC), BDBM13063, CTK8E7482, KBio2_002227, KBio2_004795, KBio2_007363, KBio3_001941, KS-00000XKX, EX-A241, MolPort-000-883-874, HMS1922J21, HMS2051P07, HMS2232P23, HMS3372D12, HMS3393P07, HMS3652I04, HMS3715L18, Pharmakon1600-01504302, BCP02419, Tox21_111438, ABP000351, AC-120, CCG-39589, MFCD00950568, NSC759846, s4049, AKOS000280920, Tox21_111438_1, API0004561, CS-1674, DB00580, NC00184, NSC-759846, RL02316, MRF-0000216, NCGC00095129-02, NCGC00095129-03, NCGC00095129-06, Valdecoxib, analytical reference material, AJ-08285, AN-16123, BC209355, CC-35561, CPD000466327, HY-15762, KB-62216, SAM001246603, SC-19235, ZB000648, ACM1189428236, AB0125618, AX8016203, LS-173713, RT-016210, UNM-0000305814, 4CH-003246, FT-0631199, ST24042991, C21552, D02709, AB00639996-08, AB00639996_10, 695V727, A812629, C-19398, SR-01000759421, J-011613, J-513600, SR-01000759421-4, 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamide, BRD-K12994359-001-02-8, BRD-K12994359-001-14-3, I14-44902, 4-(5-Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide, Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI), Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI), InChI=1/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20, VLX